An international company based in Parma (Italy) with 80 years of experience and a strong focus on research, development, production and the commercialisation of innovative medicines in the Respiratory, Neonatology, Rare Disease and Special Care Therapeutic Areas. With a turnover of more than €1.3 billion sales Chiesi is among the top 50 pharmaceutical companies in the world. Production sites are in Parma, Italy, Blois (France) and Santana De Parnaiba (Brazil). They opened their Mexican affiliate in 2012.
Av. Coyoacán No. 1622
Edificio 2, Piso 1 Oficina 208
Col. Del Valle, Benito Juárez
C.P. 03100, México, D.F.
Asist. +52 (55) 4040-7200
Direct. +52 (55) 4040-7201
Mob. +52 1 (55) 4488-7202
e-mail. m.muniz@chiesi.com
website. www.chiesi.mx
Chiesi Mexico’s Marco Ruggiero discusses his initial impressions of the Mexican pharma market, his strategic priorities for the affiliate, and the increasing importance of the company’s respiratory portfolio in Mexico.…
Mario Muniz, general manager of Chiesi Mexico, explains how the affiliate looks at becoming a comprehensive solution provider in the neonatal field, highlights the dramatic consequences of the health budget…
Internationalization and innovation are part of Chiesi’s history. The general manager of the recently started Mexican affiliate discusses the company’s priorities for the second largest market in Latin America and…
Nuclear medicine is not a concept we are familiar with. Could you give us a brief breakdown of what encompasses nuclear medicine? Nuclear medicine works the following way: a small…
Convatec acquired Boston Medical Device in September 2011. Which have been the major challenges following the acquisition, and which synergies are to be expected? The story of BMD would suffice…
Baxter established itself in Mexico as early as 1948 through the acquisition of a local manufacturer, Madom’s Pharmaceutical. In a vast market like France, operations started 40 years ago; in…
Hospira Mexico is not only the control centre for Central America and Caribbean operations, but it is the Latin American regional office. Why was such importance given to Mexico in…
Biofarma Natural CMD started operations in 1992 as a company focused on natural products. Please can you give us an insight into how the company has grown since then? I…
Carnot is celebrating 70 years as a company. There have been a lot of changes over this time, but more specifically over the last three to four years, please can…
We understand that Mexico has a lot of advantages for holding clinical trials, including the large population, access to specialized patient populations, higher patient retention rates and cheaper costs by…
The Aspen Group identified Latin America as a “large developing market where it can leverage its substantial intellectual property portfolio and manufacturing infrastructure”. What was the original strategy behind getting…
You took over BOMI as President and CEO only last year. Could you give us a brief background on BOMI Mexico and yourself? BOMI Mexico was founded in 1995. The…
Over ten years ago, the economic concept of the ‘BRIC’ countries- Brazil, Russia, India and China – was formed, and it’s pretty much all we’ve heard about ever since.…
Despite being in the Mexican market for over twenty years, biosimilars have never been regulated as a separate entity. They have always been regulated as simply another category of generic…
We read in an article by El Economista last year that you believe “there is no other company with such a diverse range of therapies as MSD and that makes…
See our Cookie Privacy Policy Here
